Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | November 20, 2014 |
| Target | Potentia Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Apellis Pharmaceuticals |
| Deal Type | Add-on Acquisition |
FILTER BY
| Category | Company |
|---|---|
| Founded | 2009 |
| Sector | Life Science |
| Employees | 705 |
| Revenue | 781M USD (2024) |
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company, focused on the development of a platform of novel therapeutic compounds for the treatment of a broad range of autoimmune diseases based upon complement immunotherapy. Uncontrolled complement activation can lead to a wide range of life-threatening or debilitating disorders. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. Apellis Pharmaceuticals was founded in 2009 and is headquartered in Waltham, Massachusetts.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Add-on Acquisition | 1 of 1 |
| State: Kentucky | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2014 | 1 of 1 |
